failure to current IL-17i or severe psoriasis, â€¡ or if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease. Switch to an IL-12/23i biologic over adding MTX to an IL-17i biologic (PICO 40) Very low Conditional recommendation based on very-low-quality evidence; may consider adding MTX to an IL-17i if the patient had had a partial response to the existing regimen. In adult patients with